bioAffinity Technologies Receives Japan Patent Allowance for CyPath Lung Early Lung Cancer Test

bioAffinity Technologies, Inc.

Japan Patent Office issued a Notice of Allowance for bioAffinity's method of predicting lung cancer likelihood using the CyPath Lung test and AI-built algorithm.
Patent would be the first awarded in Japan for CyPath Lung and the fifth protecting the early lung cancer test in Asia, including China and Hong Kong.
bioAffinity's portfolio includes 22 awarded U.S. and foreign patents and 36 pending applications; issuance expected after payment of applicable fee.
CEO Maria Zannes said the patent strengthens IP protection in Asian markets; CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy, and 99% NPV.
Company trades on Nasdaq Capital Market under BIAF for common stock and BIAFW for warrants to purchase common stock.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.